A recent trial investigating treatment for diabetic macular edema has led to drug dosages being questioned by experts.
The Diabetic Retinopathy Clinical Research Network (DRCNW) revealed findings of their Protocol T comparison study at the American Society of Retina Specialists (ASRS) 2015 Annual Meeting.
In the Protocol T study, 660 people with diabetic macular edema – which can lead to problems with central vision – either received 2.0mg of aflibercept, 1.25mg of bevacizumab or 0.3mg of ranibizumab.
After a year of treatment, patients in the aflibercept group had developed more lines of vision, but this was only attributed to patients in each group who had the most severe loss of vision.
Dr. David Brow, MD, Baylor College of Medicine, United States reported that if the dose of bevacizumab or ranibizumab had been increased, the results may have been equivalent with aflibercept.
The researchers added that while the US Food and Drug Administration (FDA) approved ranibizumab at 0.3mg, other countries have approved it for use at 0.5mg.
There were no apparent differences between the study groups, on average, and these findings highlight how instrumental dosage levels could be in treating macular edema.
The DRCNW are now working on a new trial to assess which drug works best for macular edema patients.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…